Table 5. Pharmacological Intervention.
| Statements | Level of Evidence* | Median Response | n/N (%)1 |
|---|---|---|---|
| Bisphosphonates should be used if the International Society for Clinical Densitometry criteria for osteoporosis in children and adolescents are fulfilled | 1,2 | Agree | 17/23 (73.9) |
| The intravenous dosage of Bisphosphonates should follow evidence-based protocols | 4 | Agree | 16/22 (72.7) |
| Reassess bone mineral content and areal bone mineral density one year after Bisphosphonate therapy to decide on further therapy | 4 | Agree | 24/26 (92.3) |
| If reassessment of bone mineral content and areal bone mineral density shows limited response, review the therapeutic approach | 4 | Agree | 23/26 (88.5) |
| If hormonal intervention for regulation of the menstrual cycle is needed, use of Depot medroxyprogesterone acetate (DMPA) should be avoided | 1,2 | Agree | 21/21 (100) |
| Although Levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) does not negatively affect bone density, communication difficulties during insertion need to be considered | 4 | Agree | 15/15 (100) |
*Scottish Intercollegiate Guidelines network
1Numerator is the number of responses with median response or 1 category either side and denominator is the number of clinicians in the panel whose expertise were relevant to this item